Oncology nursing drug handbook
著者
書誌事項
Oncology nursing drug handbook
Jones and Bartlett, c2000-
- 2000
- 2003
- 2004
- 2005
- 2006
- 2008
- 2014
- タイトル別名
-
Two thousand oncology nursing drug handbook
Oncology nursing drug handbook
大学図書館所蔵 件 / 全8件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
2000: Rev. ed. of: 1999 oncology nursing drug handbook, c1999
2005, 2006, 2008, 2014: [by] Gail M. Wilkes, Margaret Barton-Burke
Includes bibliographical references and index
内容説明・目次
- 巻冊次
-
2000 ISBN 9780763711658
内容説明
Nurses are actively involved in all phases of cancer management, inclu ding pharmacologic management, symptom management, and management of c omplications of disease and treatment. This comprehensive reference fo cuses on the nursing process throughout, and uses it as a framework fo r assessment, intervention, and patient education. The 2000 edition of "Oncology Nursing Drug Handbook" has been updated to include new chem otherapy drugs and new drugs used in symptom management. The book prov ides easy to use, critical drug information for the practicing oncolog y nurse to use in areas such as the management of pain, and chemothera py administration. In addition, the book contains updated resources su ch as a quick reference table for drugs used in the management of HIV infections, and drug interactions.
- 巻冊次
-
2003 ISBN 9780763721411
内容説明
2003 Oncology Nursing Drug Handbook is a comprehensive nursing resource for assessment, intervention, and patient education in the administration of oncology drugs. This essential reference provides valuable information on symptom management and chemotherapy administration for the oncology nurse. For 2003 it has been updated with the latest chemotherapy and symptom management drugs.
- 巻冊次
-
2005 ISBN 9780763730581
内容説明
A comprehensive nursing resource for assessment, intervention, and patient education in the administration of oncology drugs.
- 巻冊次
-
2006 ISBN 9780763739232
内容説明
2006 Oncology Nursing Drug Handbook is a comprehensive nursing resource for assessment, intervention, and patient education in the administration of oncology drugs. This text reviews drug information from the nurse's point of view, and helps the nurse focus on minimizing toxicity. This essential reference provides valuable information on effective symptom management and chemotherapy administration for the oncology nurse. Updated annually, the 2006 edition includes the following new drugs: four antineoplastic agents (clofarabine, histrelin implant, paclitaxel protein bound particles for injection, TLK 286), four antimicrobial agents (micafungin, rifaximin, gemifloxacin, tigecycline), two immunotherapy/biotherapy symptom management agents (Imiquimod 5% cream., palifermin), and eight molecularly targeted drugs (lapatanib, panitumumab, pertuzumab, sorafeni (BAY 43-9006), sunitinib malate (sutent, SU11246), temsirolimus, tipifarnib, vatalanib), and one symptom management drug (ziconotide intrathecal infusion). In addition, indications and additional toxicity data have been updated for individual drugs, such as bevacizumab, cetuximab, and gefitinib.
- 巻冊次
-
2004 ISBN 9780763748517
内容説明
2004 Oncology Nursing Drug Handbook is a comprehensive nursing resource for assessment, intervention, and patient education in the administration of oncology drugs. This essential reference provides valuable information on symptom management and chemotherapy administration for the oncology nurse. For 2004 it has been updated with the latest chemotherapy and symptom management drugs.
- 巻冊次
-
2014 ISBN 9781284043938
内容説明
Written especially for nurses caring for patients with cancer, the 2014 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.
Completely revised and updated, the 2014 Oncology Nursing Drug Handbook includes:
* New chapter on Chemobiotherapy for Noncancer Diseases
* Specific drugs described in terms of their mechanism of action, metabolism, drug interactions, laboratory effects/interference, and special considerations
* The most important and common drug side effects
* Greater discussion of fundamentals of malignant transformation, new molecular targets, and drugs in the pipeline
New drug entries include: enzalutamide, omacetaxine (Synribo), tbo-filgrastim (Netroval), ado-trastuzumab emtansine, aflibercept, bosutinib, cabozantinib, carfilzomib, dabrafenib, pomalidomide, ponatinib, regorafenib, trametinib, abatacept (Orencia), adalimumab (Humira), certolizumab pegol (CIMZA), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), tocilizumab (Actemra), and tofacitinib (Xeljanz).
「Nielsen BookData」 より
